Humacyte
HUMA
78 hedge funds and large institutions have $43.1M invested in Humacyte in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 27 increasing their positions, 18 reducing their positions, and 13 closing their positions.
62% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 13
50% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 18
10% more funds holding
Funds holding: 71 → 78 (+7)
1.62% more ownership
Funds ownership: 11.43% → 13.05% (+1.6%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
48% less capital invested
Capital invested by funds: $83.1M → $43.1M (-$39.9M)
59% less call options, than puts
Call options by funds: $332K | Put options by funds: $806K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.55M |
| 2 |
LPL Financial
San Diego,
California
|
+$1.65M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.4M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$991K |
| 5 |
State Street
Boston,
Massachusetts
|
+$983K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$1.02M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$867K |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
-$745K |
| 4 |
Squarepoint
New York
|
-$420K |
| 5 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$352K |
HUMA Hedge Fund Activity: Q2 2022 in Review
78 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q2 2022, worth a combined $43.1M — down 48% from $83.1M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new HUMA positions and 13 closed out — a net gain of 8 holders — while 27 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $4.55M. The largest seller was UBS O'Connor, cutting an estimated $1.02M.
- 78 institutional investors held Humacyte (HUMA) as of Q2 2022, up from 71 in Q1 2022.
- Funds reported $43.1M of Humacyte stock for Q2 2022, down 48% quarter-over-quarter.
- 21 funds opened new Humacyte positions in Q2 2022 and 13 closed out, a net change of +8 holders.
- The largest Humacyte buyer in Q2 2022 was BlackRock, an estimated $4.55M added.
- The largest Humacyte seller in Q2 2022 was UBS O'Connor, an estimated $1.02M sold.
Based on aggregated 13F filings for Q2 2022.